Daniel J. Stieh

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts.

Associations between the microbiome and immune responses to an adenovirus-based HIV-1 candidate vaccine are distinct between African and US cohorts.

Journal: mSystems
Published: January 15, 2026

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.

Journal: NPJ vaccines
Published: December 05, 2025

Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection.

Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection.

Journal: NPJ vaccines
Published: October 02, 2025

Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320.

Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320.

Journal: EBioMedicine
Published: August 24, 2025

Design, Structure, and Immunogenicity of a Soluble Prefusion-stabilized EBV gB Antigen.

Design, Structure, and Immunogenicity of a Soluble Prefusion-stabilized EBV gB Antigen.

Journal: bioRxiv : the preprint server for biology
Published: July 15, 2025

Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen.

Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen.

Journal: Nature communications
Published: May 18, 2025

Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.

Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The lancet. HIV
Published: March 06, 2025

A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses.

A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses.

Journal: Nature communications
Published: February 21, 2025

Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trial.

Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trial.

Journal: EBioMedicine
Published: October 03, 2024

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Journal: EBioMedicine
Published: September 27, 2024

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.

Journal: PLOS global public health
Published: September 05, 2024

Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

Journal: Journal of virology
Published: July 24, 2024
Showing 1-12 of 46

Last Updated: 09/26/2026